Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
OP011:Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Peyrin-Biroulet L.
Last Modified: Wednesday, 15 March 2017, 2:47 PM by ECCO Administrator
Etrolizumab
Files: 1
OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch- anal anastomosis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ferrante M.
Last Modified: Wednesday, 15 March 2017, 2:49 PM by ECCO Administrator
Ulcerative colitis, Ileo anal pouch procedure, Post operative complications, Post operative medical management, Vedolizumab
Files: 1
OP013: Disease management and outcomes of patients with Crohn’s Disease at high risk of recurrence. Results from PRACTICROHN study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Iborra M.
Last Modified: Wednesday, 15 March 2017, 2:52 PM by ECCO Administrator
Colonscopy, Ileo caecal resection, Post operative complications, Post operative medical management, Thiopurines ( AZA / MP )
Files: 1
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Sazonovs Aleksejs
Created: Friday, 23 March 2018, 12:23 PM
Last Modified: Thursday, 5 July 2018, 10:50 AM by Lindley Fritze
OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome
Year: 2018
Source: ECCO'18 Vienna
Authors: Vich Vila Arnau
Created: Friday, 23 March 2018, 12:23 PM
Last Modified: Thursday, 5 July 2018, 10:51 AM by Lindley Fritze
Files: 1
OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Last Modified: Wednesday, 15 March 2017, 2:49 PM by ECCO Administrator
Ozanimod, Histological remission
Files: 1
OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn’s Disease: Data from CALM
Year: 2018
Source: ECCO'18 Vienna
Authors: Reinisch Walter
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIR!C TRIAL
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Groof J.
Last Modified: Wednesday, 15 March 2017, 2:47 PM by ECCO Administrator
Crohn's disease, Ileo caecal resection, Laparoscopic surgery, Infliximab
Files: 1
OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014
Year: 2018
Source: ECCO'18 Vienna
Authors: Kalman Disa
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP016: Potential role of bile acid receptor FXR in microscopic colitis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Palmela C.
Last Modified: Wednesday, 15 March 2017, 2:17 PM by Vesna Babaja
Histology, Microscopic colitis
Files: 1
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Jong M.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by Vesna Babaja
Disease activity Indices, Patient reported outcomes, Quality of life, IBD nurse
Files: 1
OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database
Year: 2018
Source: ECCO'18 Vienna
Authors: Pellino Gianluca
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling
Year: 2018
Source: ECCO'18 Vienna
Authors: Elangovan Sudharshan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kanis S.
Last Modified: Wednesday, 15 March 2017, 2:22 PM by Vesna Babaja
Anti TNF drug levels, Anti TNF agents, IBD in pregnancy
Files: 1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Last Modified: Wednesday, 15 March 2017, 2:34 PM by ECCO Administrator
Mongersen
Files: 1
OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)
Year: 2018
Source: ECCO'18 Vienna
Authors: Paramsothy Sudarshan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jean-Frédéric Colombel
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP01: In-depth characterization of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Shixian Hu
Created: Tuesday, 28 May 2019, 3:32 PM
Genetic factors, Microbiota, Crohn’s disease, Ulcerative colitis, Genetics, Microbiota
Files: 1
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gils A.
Last Modified: Wednesday, 15 March 2017, 2:33 PM by ECCO Administrator
Therapeutic drug monitoring, Pharmacokinetics, Vedolizumab
Files: 1
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dulai P.
Last Modified: Wednesday, 15 March 2017, 2:31 PM by ECCO Administrator
Files: 1